Study of the efficacy of memantine in metastatic colon cance
Phase 2
Recruiting
- Conditions
- Metastatic colon cancer.Malignant neoplasm of colon
- Registration Number
- IRCT20210819052230N1
- Lead Sponsor
- Oroumia University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
All patients over 18 years of age with metastatic colon cancer
Exclusion Criteria
Severe renal failure
Liver failure (more than 5-fold increase in liver enzymes)
History of memantine allergy
History of seizures
Cardiovascular disease
Eye diseases
Concomitant use of drugs that alter the pH of the urine.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quality of life in patient with colon cancer. Timepoint: Beginning and end of the study (third month). Method of measurement: QLQ-C30 Questionnaire.;The size of tumor in patients with colon cancer. Timepoint: Beginning and end of the study (third month). Method of measurement: CT scan.
- Secondary Outcome Measures
Name Time Method Vascular endothelial growth factor (VEGF). Timepoint: Beginning and end of the study (third month). Method of measurement: ELISA kit.;Carcinoembryonic Antigen (CEA). Timepoint: Beginning and end of the study (third month). Method of measurement: ELISA kit.;Body Mass Index (BMI). Timepoint: Beginning and end of the study (third month). Method of measurement: weight kg/height m2.